Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2022-02-01 00:00:00 ET · period of report 2022-01-31 · accession 0001104659-22-010396 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-01 | 2022-01-31 | SLS | Stergiou Angelos M. | Pres, CEO, Dir | A - Grant | $0.00 | +44.0K | 165.2K | +36% | $0 |
| D | 2022-02-01 | 2022-01-31 | SLS | Stergiou Angelos M. | Pres, CEO, Dir | A - Grant | $0.00 | +165.0K | 165.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-31 | A | A | 44,000 | $0.00 | 165,167 | D | — | — | (F1) The Reporting Person received an award of 44,000 restricted stock units on January 31, 2022, which shall vest as follows: (i) 25% on December 1, 2022 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-31 | A | A | 165,000 | $0.00 | 165,000 | D | $5.34 · — to 2032-01-31 | 165,000 Common Stock | (F2) One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 31, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |